1.53
前日終値:
$1.55
開ける:
$1.57
24時間の取引高:
213.28K
Relative Volume:
0.44
時価総額:
$47.95M
収益:
-
当期純損益:
$-51.50M
株価収益率:
-0.3825
EPS:
-4
ネットキャッシュフロー:
$-47.10M
1週間 パフォーマンス:
+5.52%
1か月 パフォーマンス:
+9.29%
6か月 パフォーマンス:
-71.88%
1年 パフォーマンス:
-81.32%
Outlook Therapeutics Inc Stock (OTLK) Company Profile
名前
Outlook Therapeutics Inc
セクター
電話
(609) 619-3990
住所
111 S. WOOD AVENUE, ISELIN, NJ
OTLK を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
OTLK
Outlook Therapeutics Inc
|
1.53 | 47.95M | 0 | -51.50M | -47.10M | -4.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-02 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
2024-03-27 | アップグレード | BTIG Research | Neutral → Buy |
2024-02-15 | アップグレード | Chardan Capital Markets | Neutral → Buy |
2024-01-25 | アップグレード | Guggenheim | Neutral → Buy |
2023-12-27 | アップグレード | CapitalOne | Equal Weight → Overweight |
2023-08-31 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
2023-08-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2023-08-30 | ダウングレード | BTIG Research | Buy → Neutral |
2023-08-30 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2023-08-30 | ダウングレード | CapitalOne | Overweight → Equal Weight |
2023-08-30 | ダウングレード | Guggenheim | Buy → Neutral |
2023-07-13 | 開始されました | CapitalOne | Overweight |
2023-04-03 | 開始されました | Guggenheim | Buy |
2023-02-06 | 開始されました | Cantor Fitzgerald | Overweight |
2022-10-31 | 開始されました | BTIG Research | Buy |
2022-09-13 | 開始されました | Chardan Capital Markets | Buy |
2019-09-11 | 開始されました | Ladenburg Thalmann | Buy |
2019-05-16 | 開始されました | Oppenheimer | Outperform |
2019-04-22 | 開始されました | Ascendiant Capital Markets | Buy |
すべてを表示
Outlook Therapeutics Inc (OTLK) 最新ニュース
Press Release Distribution & PR Platform - ACCESS Newswire
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - ADVFN
Age Related Vision Dysfunction Market to Reach New Heights - openPR.com
Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail
25,615 Shares in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Acquired by Commonwealth Equity Services LLC - Defense World
Outlook Therapeutics Approves Retention Incentive for CFO - MSN
Henlius And Outlook Move Forward With Ophthalmic Bevacizumab - insights.citeline.com
Guggenheim maintains Buy on Outlook Therapeutics, target $10 By Investing.com - Investing.com Canada
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
FDA accepts updated biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD - Optometry Times
Guggenheim maintains Buy on Outlook Therapeutics, target $10 - Investing.com
FDA sets August 27 review date for Outlook Therapeutics’ eye drug By Investing.com - Investing.com South Africa
Outlook Therapeutics Says FDA Acknowledged Receipt Of Co's BLA ResubmissionSEC Filing - marketscreener.com
Outlook Therapeutics (OTLK) Soars After FDA Accepts ONS-5010 for Review - GuruFocus
OTLKWOutlook Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Outlook Therapeutics gets FDA review acceptance for wet AMD treatment - Seeking Alpha
Outlook Therapeutics Says FDA Accepts Biologics License Application for Wet AMD Treatment - MarketScreener
FDA sets August 27 review date for Outlook Therapeutics' eye drug - Investing.com
FDA sets August 27 review date for Outlook Therapeutics’ eye drug - Investing.com India
Outlook Therapeutics Resubmits BLA For ONS-5010 In Wet AMD - Nasdaq
Outlook Therapeutics® Announces Acceptance of Biologics - GlobeNewswire
Major FDA Milestone: Novel Wet AMD Drug Gets Review Date, Could Be First-of-its-Kind Approval - Stock Titan
Charles Schwab Investment Management Inc. Sells 15,411 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Bought by Bank of New York Mellon Corp - Defense World
Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Outlook Therapeutics Files Prospectus Covering Offer & Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common Stock - Marketscreener.com
Outlook Therapeutics expands share authorization - Investing.com Australia
Outlook Therapeutics Issues Convertible Note to Avondale - TipRanks
Outlook Therapeutics expands share authorization By Investing.com - Investing.com UK
Rhumbline Advisers Purchases 174,896 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire
INVESTOR ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire
Outlook Therapeutics® Re-Submits Biologics License - GlobeNewswire
Outlook Therapeutics Resubmits BLA For ONS-5010, A Proposed Treatment For Wet AMD - Nasdaq
Outlook Therapeutics Resubmits Biologics License Application By Investing.com - Investing.com South Africa
Outlook Therapeutics Resubmits BLA For ONS-5010 To FDA In Wet AMD - Nasdaq
Outlook Therapeutics Resubmits Biologics License Application - Investing.com
Can Outlook's Eye Treatment Win FDA Approval Despite Missing Primary Endpoint? - StockTitan
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024 – OTLK - ACCESS Newswire
Outlook Therapeutics (NASDAQ:OTLK) Given New $24.00 Price Target at Ascendiant Capital Markets - Defense World
HC Wainwright Issues Pessimistic Forecast for OTLK Earnings - MarketBeat
Equities Analysts Offer Predictions for OTLK Q1 Earnings - MarketBeat
vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga
HC Wainwright Has Pessimistic Outlook of OTLK Q2 Earnings - Defense World
What is HC Wainwright’s Estimate for OTLK Q1 Earnings? - Defense World
Outlook Therapeutics Inc (OTLK) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):